Pharmacologic Properties of Proton Pump Inhibitors

Pharmacologic properties of proton pump inhibitors.

Since their introduction into clinical practice in the 1980s, proton pump inhibitors (PPIs) have proved to be of enormous value in the management of acid peptic disorders. They have become the treatment of choice for most, if not all, acid-related gastrointestinal disorders, including gastroesophageal reflux disease, peptic ulcer, and Zollinger-Ellison syndrome. With approval of an intravenous ...

Proton Pump Inhibitors: Omeprazole

Oral Proton Pump Inhibitors

There is currently a lack of evidence to suggest superior clinical efficacy of one oral proton pump inhibitor over any other. Proton pump inhibitors display similar doseresponse relationships with similar potencies and efficacies at the equivalent dose. The decision to select one proton pump inhibitor over another is likely to be based on the agents’ licensed indication, patient tolerability an...

Intravenous proton pump inhibitors.

Intravenous (IV) administration of a proton pump inhibitor (PPI) is a faster way to achieve gastric acid suppression than oral administration of the same agent. Peak suppression after IV administration occurs within hours, compared with several days later after oral administration. Thus the IV route of administration offers a faster onset of gastric suppression, achievement of intragastric pH c...

Anti-Inflammatory and Anti-Oxidative Properties of Proton Pump Inhibitors

Gastric acid-dependent diseases, i.e. gastroesophageal reflux disease and peptic ulcers, are the leading causes of heart burn, epigastralgia, and dyspeptic symptoms. Gastric acid suppressing intervention have demonstrated a marked reduction in subjective symptoms as well as ulcer healing. Proton pump inhibitors (PPIs) have been widely used for the treatment of these diseases and Helicobacter py...